Evidence map›Paper›PMID 33918794›Full record

ArticleCancers2021

Musashi-1 Regulates MIF1-Mediated M2 Macrophage Polarization in Promoting Glioblastoma Progression.

Yi-Ping Yang, Chian-Shiu Chien, Aliaksandr A Yarmishyn, Man-Sheung Chan, Andy Chi-Lung Lee, Yi-Wei Chen, Pin-I Huang, Hsin-I Ma, Wen-Liang Lo, Yueh Chien and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. BSA-MnORSC advances · 2021
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yi-Ping YangDivision of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Chian-Shiu ChienDivision of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.ORCID 0000-0001-9666-1273
Aliaksandr A YarmishynDivision of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.ORCID 0000-0002-0097-9541
Man-Sheung ChanDivision of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Andy Chi-Lung LeeDivision of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Yi-Wei ChenSchool of Medicine, National Yang-Ming Chiao-Tung University, Taipei 112, Taiwan.
Pin-I HuangSchool of Medicine, National Yang-Ming Chiao-Tung University, Taipei 112, Taiwan.
Hsin-I MaDepartment of Neurological Surgery, Tri-Service General Hospital and National Defense Medical Center, Taipei 114, Taiwan.
Wen-Liang LoSchool of Medicine, National Yang-Ming Chiao-Tung University, Taipei 112, Taiwan.ORCID 0000-0002-8484-0095
Yueh ChienDivision of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Wen-Chang LinInstitute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
Mong-Lien WangDivision of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Ming-Teh ChenSchool of Medicine, National Yang-Ming Chiao-Tung University, Taipei 112, Taiwan.ORCID 0000-0002-4060-9131
National Yang Ming Chiao Tung University · TWInstitute of Biomedical Sciences, Academia Sinica · TWTri-Service General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most malignant brain tumor which is characterized by high proliferation and migration capacity. The poor survival rate has been attributed to limitations of the current standard therapies. The search for novel biological targets that can effectively hamper tumor progression remains extremely challenging. Previous studies indicated that tumor-associated macrophages (TAMs) are the abundant elements in the tumor microenvironment that are closely implicated in glioma progression and tumor pathogenesis. M2 type TAMs are immunosuppressive and promote GBM proliferation. RNA-binding protein Musashi-1 (MSI1) has recently been identified as a marker of neural stem/progenitor cells, and its high expression has been shown to correlate with the growth of GBM. Nevertheless, the relationship between MSI1 and TAMs in GBM is still unknown. Thus, in our present study, we aimed to investigate the molecular interplay between MSI1 and TAMs in contributing to GBM tumorigenesis. Our data revealed that the secretion of macrophage inhibitory factor 1 (MIF1) is significantly upregulated by MSI1 overexpression in vitro. Importantly, M2 surface markers of THP-1-derived macrophages were induced by recombinant MIF1 and reduced by using MIF1 inhibitor (S,R)-3-(4-hHydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid (ISO-1). Furthermore, GBM tumor model data suggested that the tumor growth, MIF1 expression and M2 macrophage population were significantly downregulated when MSI1 expression was silenced in vivo. Collectively, our findings identified a novel role of MSI1 in the secretion of MIF1 and the consequent polarization of macrophages into the M2 phenotype in promoting GBM tumor progression.

Indexed as

glioblastoma progressionISO-1M2 macrophagesmacrophage inhibitory factorMusashi-1

Identifiers

PMID33918794
PMCPMC8069545
OpenAlexW3156115681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.